Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
Sept 22 (Reuters) - Gilead Sciences Inc GILD.O:
ENSOMA ANNOUNCES $53 MILLION FINANCING TO SUPPORT KEY CLINICAL MILESTONES FOR EN-374 AND CONTINUED DEVELOPMENT OF IN VIVO HEMATOPOIETIC STEM CELL ENGINEERING PIPELINE
ENSOMA : INVESTORS INCLUDE GILEAD WHICH HAS ALSO APPOINTED AN EXECUTIVE TO ENSOMA BOARD OF DIRECTORS AS PART OF ITS INVESTMENT
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








